7MM HIV market to be valued at $32.1b by 2033

Thanks to the increased uptake of long-acting injectable therapies.

The human immunodeficiency virus (HIV) market across seven major markets (7MM) is expected to reach $32.1b by 2033 at a compound annual growth rate of 1.9%, said GlobalData.

The HIV market’s expansion is attributed to the increased uptake of long-acting injectable therapies, along with the anticipated launch of novel single-tablet regimens (STRs)

“The pipeline analysis indicates a shift away from 3-drug STRs and towards 2-drug STRs. These are hoped to have reduced toxicities and side effects as a result,” said Anaelle Tannen, Infectious Disease Analyst at GlobalData.

Six products are currently in Phase III development and are expected to launch by 2033, including four two-drug STRs.

Meanwhile, long-acting injectable therapies are expected to gain significant market share across the 7MM.

“This method requires infrequent dosing and is thus more convenient,” Tannen added.

7MM = US, France, Germany, Italy, Spain, UK, and Japan.